文献速递肝病

丙肝治愈后的生存:理解治愈之外的死亡与存活

Surviving Hepatitis C-Understanding Death and Survival Beyond Cure.
PubMed 文献 · Aliment Pharmacol Ther · 2025-06-19

研究纳入2016至2021年接受直接抗病毒药物(DAA)治疗的3619例成人丙肝患者,随访至2023年9月,中位随访6.8年,423例(11.7%)死亡,其中40.6%死于肝病。肝硬化、FIB4>3.25、未获持续病毒学应答(SVR)和年龄≥60岁增加肝相关死亡风险;非SVR患者死亡率32.4% vs SVR患者10.2%(p<0.001)。结论认为肝相关死亡驱动肝硬化患者死亡,治愈丙肝仍至关重要,整体照护或可降低超额死亡。

要点

  • 肝硬化(adj-HR=14.51)、FIB4>3.25(adj-HR=4.22)、非SVR(adj-HR=3.94)、年龄≥60岁(adj-HR=1.88)增加肝相关死亡风险。
  • 非SVR患者死亡率32.4% vs SVR患者10.2%(p<0.001),非SVR增加肝死亡风险(adj-HR=4.30)。
  • 精神科药物使用(adj-HR=2.82)、失访(adj-HR=2.61)、注射吸毒/阿片替代治疗(adj-HR=2.26)增加自残/意外中毒死亡风险。

核心结论

  • 肝相关死亡驱动肝硬化患者的死亡。
  • 治愈丙肝仍然至关重要。
  • 整体丙肝照护,关注年轻患者的精神健康疾病、代谢合并症以及对老年患者更好的癌症筛查,可能降低超额死亡。

研究设计与样本

  • 研究纳入2016至2021年招募的接受DAA治疗的成人丙肝患者,随访至2023年9月。
  • 从人口数据库获取用药、医疗服务使用和死亡信息。
  • 主要结局为全因死亡和死因别死亡。

主要发现

  • 共3619例患者,平均年龄52.0岁(SD=10.5),66.0%为男性,33.6%有肝硬化,中位随访6.8年(IQR 5.5-7.4)。
  • 423例(11.7%)死亡,其中40.6%死于肝病,13.2%死于自残/意外中毒,12.3%死于呼吸系统疾病/肺癌。
  • 肝硬化(adj-HR=14.51,95%CI 6.87-30.64)、FIB4>3.25(adj-HR=4.22,95%CI 2.63-6.80)、非SVR(adj-HR=3.94,95%CI 2.64-5.88)和年龄≥60岁(adj-HR=1.88,95%CI 1.32-2.69)增加肝相关死亡风险。
  • 非SVR患者死亡率32.4%(210例中) vs SVR患者10.2%(2894例中),p<0.001;非SVR增加肝死亡风险(adj-HR=4.30,95%CI 2.90-6.37)。
  • 精神科药物使用(adj-HR=2.82,95%CI 1.40-5.67)、失访(adj-HR=2.61,95%CI 1.31-5.21)、注射吸毒/阿片替代治疗(adj-HR=2.26,95%CI 1.23-4.14)增加自残/意外中毒相关死亡风险;年龄≥60岁和糖尿病增加其他肝外癌症死亡风险(adj-HR=2.68,95%CI 1.31-5.51和adj-HR=2.57,95%CI 1.15-5.72)及心血管疾病死亡风险(adj-HR=2.71,95%CI 1.06-4.19和adj-HR=2.28,95%CI 1.03-5.05)。

临床怎么用

  • 作者认为,整体丙肝照护,关注年轻患者的精神健康疾病、代谢合并症以及对老年患者更好的癌症筛查,可能降低超额死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cure of hepatitis C virus (HCV) infection decreases liver- and all-cause mortality. However, the risk of early mortality after HCV cure remains. We examined factors associated with cause-specific mortality after direct-acting antiviral (DAA) therapy. METHODS: DAA-treated adults (recruited 2016-2021) were followed up to September 2023. Medication, health-service use, and deaths were obtained from population databases. The primary outcome was all-cause and cause-specific mortality. RESULTS: Among 3619 patients (average 52.0 years (SD = 10.5), 66.0% male, 33.6% with cirrhosis) followed for a median of 6.8 years (IQR 5.5-7.4), 423 (11.7%) died (40.6% due to liver disease, 13.2% self-harm/accidental poisoning and 12.3% respiratory disease/lung cancer). Cirrhosis (adjusted hazard ratio (adj-HR) = 14.51, 95% CI 6.87-30.64), FIB4 > 3.25 (adj-HR = 4.22, 95% CI 2.63-6.80), nonsustained virological response (SVR) (adj-HR = 3.94, 95% CI 2.64-5.88) and age ≥ 60 years (adj-HR = 1.88, 95% CI 1.32-2.69) increased liver-related mortality risk. Mortality was threefold higher in non-SVR (32.4% of 210 patients vs. 10.2% of 2894 with SVR, p < 0.001). Non-SVR increased risk of liver mortality (adj-HR = 4.30, 95% CI 2.90-6.37). Mental health medication use (adj-HR = 2.82, 95% CI 1.40-5.67), loss to clinical follow-up (adj-HR = 2.61, 95% CI 1.31-5.21) and injection drug use/opioid replacement therapy (adj-HR = 2.26, 95% CI 1.23-4.14) increased risk of self-harm/accidental poisoning-related mortality. Age ≥ 60 years and diabetes increased mortality risk from other extrahepatic cancer (adj-HR = 2.68, 95% CI 1.31-5.51 and adj-HR = 2.57, 95% CI 1.15-5.72) and cardiovascular disease (adj-HR = 2.71, 95% CI 1.06-4.19 and adj-HR = 2.28, 95% CI 1.03-5.05). CONCLUSIONS: Liver-related death drives mortality for cirrhotic patients. Curing HCV remains critical. Holistic HCV care, with attention to mental health illnesses in younger patients, metabolic comorbidities, and better cancer screening for older patients may reduce excess mortality.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Clark PJ, Valery PC, Strasser SI, et al. Surviving Hepatitis C-Understanding Death and Survival Beyond Cure. Aliment Pharmacol Ther. 2025. PMID: 40536167. doi:10.1111/apt.70219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。